Chinese biotech startup Binhui Biopharm has secured about $47 million in a Series B+ round of financing as it is rolling out clinic trials of its self-developed novel oncolytic virus drug candidate BS001 (OH2).
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
